Consilient Health has appointed Harald Stock as Non-Executive Director, following a successful search conducted by The RSA Group. A pharmaceutical company focused on the insightful, innovative commercialisation of medicines in Europe and the Middle East, the firm’s therapeutic focus is women’s health, urology and endocrinology.
An experienced executive, Stock brings a global track record of leadership and board roles in consumer healthcare, pharmaceuticals, diagnostics, medical devices and biotechnology.
Commenting on the appointment, Thomas Schleimer, Partner said: “Harald is one of those global citizens who can navigate and operate across a Life Sciences value chain and brings deep expertise from commercialisation and Board work in the EU and US. The RSA Group has again supported one of our clients in Specialty Pharma to secure an independent NED who will bring experience from turnaround, IPO, commercialisation and US listing to the organisation”